Molecular Pathology: Jan Schellens
Jan Schellens, M.D. professorGroupleader
- +31 20 512 2446
Research interest: Personalized Cancer Treatment
- Emilie van Brummelen (MSc)Ph.D. Student
- Artur BuryloTechnician
- Robin van Geel, MScPh.D. Student
- Linda Henricks, MScPh.D. Student
- Bart Jacobs, MScPh.D. Student
- Bojana MilojkovicPh.D. Student
- Ruud van der NollPh.D. Student
- Dick Pluim, BScTechnician
- Vincent de Weger, MSc M.D.Ph.D. Student
- Kristi NiinepuuMD, guest employee
Emilie van Brummelen (MSc)
I am doing my PhD in Prof. Jan Schellens' research group on the
division of Molecular Pathology. In my research I focus on phase
I/II clinical studies. I finished the Master in Pharmacy and the
Honours Programme of Pharmaceutical Sciences at Utrecht University
in the end of 2013. During my studies, I did an internship at Bayer
Pharma in Berlin, and at several pharmacies and hospitals in the
Netherlands. Next to that I worked on a research project on the
development of polyomavirus-derived virus-like particles by
directed evolution at the group of Pharmaceutics at Utrecht
University. Also I did research on the effect of broccoli on the
CYP2D6 phenotype in vitro and in vivo.
During my studies it became more and more clear that clinical research is one of my main interests. That brought me here to work on clinical trials for my PhD, to learn about all aspects of clinical research.
Robin van Geel, MSc
As a PhD-student I work on early phase clinical studies focusing on targeted anti-cancer agents and combination strategies. One of my projects involves a phase I/II study combining a BRAF inhibitor with an EGFR inhibitor in patients with BRAF mutated metastatic colorectal cancer. This experimental therapy is based on preclinical data that suggested that both BRAF and EGFR should be targeted to effectively inhibit growth of BRAF mutated colorectal cancers. Preliminary results suggest that this treatment is very effective in this selected group of patients, with tumor responses in a substantial part of the patients at the expense of very limited adverse events.
Linda Henricks, MSc
As a PhD student in the group of Prof. Jan Schellens the focus of my research is on the safety, feasibility and cost-effectiveness of genotype- and phenotype-directed individualized dosing of fluoropyrimidines. In August 2014 I finished my master in Pharmacy at the Utrecht University cum laude. During my master I did an internship at the University of California in San Francisco where I studied the Ras pathway in colorectal cancer.
Bart Jacobs, MSc
After finishing my Masters in Pharmacy in the end of 2011 (Utrecht University) I started working as a PhD student in the group of Prof. dr. J.H.M. Schellens. My research project is focused on the development and clinical testing of new oral fluoropyrimidine drugs in order to explore implications for chronotherapy. This research is supported by bioanalytical projects in order to develop and validate assays which can be applied in the clinical studies. In addition, to gain more insight in the pharmacology of oral fluoropyrimidines, I'm currently working on the development of a population based pharmacokinetic model for capecitabine.
During my medical studies I was active in performing research on
the department of Physiology and Sport Medicine. After finishing
Medical school in Belgrade, Serbia and working at the Clinical
hospital center "Dr Dragisa Misovic, Belgrade, I started working in
an international company performing clinical trials.
Currently I work as a PhD student in the group of Prof Dr Jan Schellens focusing on phase I studies. In the cooperation with Dr Dieta Brandsma we are developing new strategies targeting brain tumors and clinically testing the assay for the enumeration of circulating epithelial and melanoma tumor cells in cerebrospinal fluid.
Ruud van der Noll
I finished my Master in Pharmacy at the University of Utrecht in
2009. After working as a pharmacist for a little while, I decided
to take on a more challenging position and started working as a PhD
student for the Schellens group at the NKI.
My research mainly focuses on several phase I studies in which new compounds or new combinations of existing drugs are given to patients for the first time. In these studies we try to establish what the toxicities are and what the recommended dose is for future studies, but also investigate whether there is evidence of preliminary anti-tumor activity.
Dick Pluim, BSc
I am involved as an independent researcher in the development and validation of non-invasive predictive and pharmacodynamic biomarker assays for monitoring the effect of molecular targeted anticancer agents. These assays can be used to predict if a patient will benefit from a particular treatment. This work includes: 1. enzymatic activity assays for dihydropyrimidine dehydrogenase, thymidine synthase, and polyADPribose polymerase. 2. assays for the enumeration of circulating epithelial and melanoma tumor cells.
Vincent de Weger, MSc M.D.
In 2011 I finished medical school at the VU university. I also enrolled in the Honors program performing my own scientific project for which I was awarded the honors degree in Medicine. After medical school I have worked as a resident at Spaarne Hospital.
Currently I work as a PhD student. My work focuses on fase I and II drug development studies, both MODRA and sponsor initiated.
MD, guest employee
I am a resident of oncology in Estonia. During my 6 months internship at NKI I will learn lab techniques by contributing to the early phase clinical studies. One of the projects involves combining MEK and panHER inhibitors in patients with KRASmutated colorectal cancer. The main aim of this internship is to see and learn the hard and interesting work done before the drug is ready for prescription.
Recent publications View All Publications
Erratum to: Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA
Invest New Drugs. 2013 [Epub ahead of print]
Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R, Beijnen JH, Schellens JH.Link to PubMed
Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate
Antimicrob Agents Chemother. 2013 [Epub ahead of print]
van Hasselt JG, van Eijkelenburg NK, Huitema AD, Schellens JH, Schouten-van Meeteren AY.Link to PubMed
Mirna Ekelschot - van Diermen
+31 20 512 9127
'Support for our research to test new treatments in patients based on breakthroughs in the lab'.Support us